TY - JOUR AU - Parkin, D. M. AU - Bray, F. AU - Ferlay, J. PY - 2005 DA - 2005// TI - Global Cancer Statistics JO - CA Cancer J Clin VL - 55 UR - https://doi.org/10.3322/canjclin.55.2.74 DO - 10.3322/canjclin.55.2.74 ID - Parkin2005 ER - TY - CHAP AU - Society, A. C. PY - 2008 DA - 2008// BT - Cancer Facts and Figures ID - Society2008 ER - TY - JOUR AU - McGuire, W. P. AU - Hoskins, W. J. AU - Brady, M. F. PY - 1996 DA - 1996// TI - Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group) JO - Semin Oncol VL - 23 ID - McGuire1996 ER - TY - CHAP AU - Muggia, F. M. AU - Braly, P. S. AU - Brady, M. F. PY - 2000 DA - 2000// BT - Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study[see comment] ID - Muggia2000 ER - TY - JOUR AU - Ozols, R. F. AU - Bundy, B. N. AU - Greer, B. E. PY - 2003 DA - 2003// TI - Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study[see comment] JO - J Clin Oncol VL - 21 UR - https://doi.org/10.1200/JCO.2003.02.153 DO - 10.1200/JCO.2003.02.153 ID - Ozols2003 ER - TY - JOUR AU - Alberts, D. S. AU - Green, S. AU - Hannigan, E. V. PY - 1992 DA - 1992// TI - Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer[see comment]. [erratum appears in J Clin Oncol 1992 Sep, 10(9):1505] JO - J Clin Oncol VL - 10 ID - Alberts1992 ER - TY - JOUR AU - Munnell, E. PY - 1968 DA - 1968// TI - The changing prognosis and treatment in cancer of the ovary JO - Am J Obstet Gynecol VL - 100 ID - Munnell1968 ER - TY - JOUR AU - Griffiths, C. T. PY - 1975 DA - 1975// TI - Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma JO - Nat Cancer Inst Monog VL - 42 ID - Griffiths1975 ER - TY - JOUR AU - Eisenkop, S. M. AU - Friedman, R. L. AU - Wang, H. J. PY - 1998 DA - 1998// TI - Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study JO - Gynecol Oncol VL - 69 UR - https://doi.org/10.1006/gyno.1998.4955 DO - 10.1006/gyno.1998.4955 ID - Eisenkop1998 ER - TY - JOUR AU - Hoskins, W. J. AU - Bundy, B. N. AU - Thigpen, J. T. PY - 1992 DA - 1992// TI - The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study JO - Gynecol Oncol VL - 47 UR - https://doi.org/10.1016/0090-8258(92)90100-W DO - 10.1016/0090-8258(92)90100-W ID - Hoskins1992 ER - TY - JOUR AU - Guidozzi, F. AU - Ball, J. H. PY - 1994 DA - 1994// TI - Extensive primary cytoreductive surgery for advanced epithelial ovarian cancer JO - Gynecol Oncol VL - 53 UR - https://doi.org/10.1006/gyno.1994.1142 DO - 10.1006/gyno.1994.1142 ID - Guidozzi1994 ER - TY - JOUR AU - Bristow, R. E. AU - Tomacruz, R. S. AU - Armstrong, D. K. PY - 2002 DA - 2002// TI - Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis JO - J Clin Oncol VL - 20 UR - https://doi.org/10.1200/JCO.20.5.1248 DO - 10.1200/JCO.20.5.1248 ID - Bristow2002 ER - TY - JOUR AU - Hoskins, W. J. AU - McGuire, W. P. AU - Brady, M. F. PY - 1994 DA - 1994// TI - The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma JO - Am J Obstet Gynecol VL - 170 UR - https://doi.org/10.1016/S0002-9378(94)70090-7 DO - 10.1016/S0002-9378(94)70090-7 ID - Hoskins1994 ER - TY - JOUR AU - Eisenkop, S. M. AU - Spirtos, N. M. PY - 2001 DA - 2001// TI - What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer? JO - Gynecol Oncol VL - 82 UR - https://doi.org/10.1006/gyno.2001.6312 DO - 10.1006/gyno.2001.6312 ID - Eisenkop2001 ER - TY - JOUR AU - Rubin, S. C. AU - Randall, T. C. AU - Armstrong, K. A. PY - 1999 DA - 1999// TI - Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings JO - Obstet Gynecol VL - 93 UR - https://doi.org/10.1016/S0029-7844(98)00334-2 DO - 10.1016/S0029-7844(98)00334-2 ID - Rubin1999 ER - TY - JOUR AU - Rosenberg, B. AU - VanCamp, L. AU - Trosko, J. E. PY - 1969 DA - 1969// TI - Platinum compounds: a new class of potent antitumour agents JO - Nature VL - 222 UR - https://doi.org/10.1038/222385a0 DO - 10.1038/222385a0 ID - Rosenberg1969 ER - TY - CHAP AU - Johnson, S. W. AU - Stevenson, J. P. AU - O'Dwyer, P. J. AU - DeVita, V. T. AU - Hellman, S. AU - Rosenberg, S. A. PY - 2001 DA - 2001// BT - Cisplatin and Its Analogues PB - Lippincott Williams and Wilkins CY - Philadelphia ID - Johnson2001 ER - TY - JOUR AU - Cvitkovic, E. AU - Spaulding, J. AU - Bethune, V. PY - 1977 DA - 1977// TI - Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model JO - Cancer VL - 39 UR - https://doi.org/3.0.CO;2-C DO - 3.0.CO;2-C ID - Cvitkovic1977 ER - TY - JOUR AU - Hayes, D. M. AU - Cvitkovic, E. AU - Golbey, R. B. PY - 1977 DA - 1977// TI - High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis JO - Cancer VL - 39 UR - https://doi.org/3.0.CO;2-J DO - 3.0.CO;2-J ID - Hayes1977 ER - TY - JOUR AU - Lambert, H. E. AU - Berry, R. J. PY - 1985 DA - 1985// TI - High dose cisplatin compared with high dose cyclophosphamide in the management of advanced epithelial ovarian cancer (FIGO stages III and IV): report from the North Thames Cooperative Group JO - Br Med J (Clin Res Ed) VL - 290 UR - https://doi.org/10.1136/bmj.290.6472.889 DO - 10.1136/bmj.290.6472.889 ID - Lambert1985 ER - TY - CHAP AU - Ozols, R. F. AU - Rubin, S. C. AU - Thomas, G. M. AU - Hoskins, W. J. AU - Perez, C. A. AU - Young, R. C. PY - 2000 DA - 2000// BT - Epithelial Ovarian Cancer PB - Lippincott Williams and Wilkins CY - Philadelphia ID - Ozols2000 ER - TY - JOUR AU - Decker, D. G. AU - Fleming, T. R. AU - Malkasian, G. D. PY - 1982 DA - 1982// TI - Cyclophosphamide plus cis-platinum in combination: treatment program for stage III or IV ovarian carcinoma JO - Obstet Gynecol VL - 60 ID - Decker1982 ER - TY - JOUR AU - Omura, G. AU - Blessing, J. A. AU - Ehrlich, C. E. PY - 1986 DA - 1986// TI - A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study JO - Cancer VL - 57 UR - https://doi.org/3.0.CO;2-J DO - 3.0.CO;2-J ID - Omura1986 ER - TY - JOUR AU - Neijt, J. P. AU - ten Bokkel Huinink, W. W. AU - Burg, M. E. v. a. n. d. e. r. PY - 1984 DA - 1984// TI - Randomized trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma JO - Lancet VL - 2 UR - https://doi.org/10.1016/S0140-6736(84)90594-4 DO - 10.1016/S0140-6736(84)90594-4 ID - Neijt1984 ER - TY - CHAP PY - 1991 DA - 1991// BT - Chemotherapy in advanced ovarian cancer: an overview of randomized clinical trials ID - ref25 ER - TY - JOUR AU - Rowinsky, E. K. AU - Cazenave, L. A. AU - Donehower, R. C. PY - 1990 DA - 1990// TI - Taxol: a novel investigational antimicrotubule agent JO - J Natl Cancer Inst VL - 82 UR - https://doi.org/10.1093/jnci/82.15.1247 DO - 10.1093/jnci/82.15.1247 ID - Rowinsky1990 ER - TY - CHAP AU - Rowinsky, E. K. AU - Donehower, R. C. PY - 1995 DA - 1995// BT - Paclitaxel (taxol) ID - Rowinsky1995 ER - TY - CHAP AU - McGuire, W. P. AU - Rowinsky, E. K. AU - Rosenshein, N. B. PY - 1989 DA - 1989// BT - Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms ID - McGuire1989 ER - TY - JOUR AU - Schiff, P. B. AU - Fant, J. AU - Horwitz, S. B. PY - 1979 DA - 1979// TI - Promotion of microtubule assembly in vitro by taxol JO - Nature VL - 277 UR - https://doi.org/10.1038/277665a0 DO - 10.1038/277665a0 ID - Schiff1979 ER - TY - JOUR AU - Schiff, P. B. AU - Horwitz, S. B. PY - 1980 DA - 1980// TI - Taxol stabilizes microtubules in mouse fibroblast cells JO - Proc Natl Acad Sci USA VL - 77 UR - https://doi.org/10.1073/pnas.77.3.1561 DO - 10.1073/pnas.77.3.1561 ID - Schiff1980 ER - TY - JOUR AU - Manfredi, J. J. AU - Parness, J. AU - Horwitz, S. B. PY - 1982 DA - 1982// TI - Taxol binds to cellular microtubules JO - J Cell Biol VL - 94 UR - https://doi.org/10.1083/jcb.94.3.688 DO - 10.1083/jcb.94.3.688 ID - Manfredi1982 ER - TY - JOUR AU - Ringel, I. AU - Horwitz, S. B. PY - 1991 DA - 1991// TI - Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol JO - J Natl Cancer Inst VL - 83 UR - https://doi.org/10.1093/jnci/83.4.288 DO - 10.1093/jnci/83.4.288 ID - Ringel1991 ER - TY - CHAP AU - Calvert, A. H. AU - Harland, S. J. PY - 1982 DA - 1982// BT - Early studies with cisdiamine 1, 1, cyclobutane dicarboxylate platinum II ID - Calvert1982 ER - TY - JOUR AU - Curt, G. A. AU - Grygiel, J. J. AU - Corden, B. J. PY - 1983 DA - 1983// TI - A phase I and pharmacokinetic study of diamminecyclobutane-dicarboxylatoplatinum (NSC 241240) JO - Cancer Res VL - 43 ID - Curt1983 ER - TY - JOUR AU - Evans, B. D. AU - Raju, K. S. AU - Calvert, A. H. PY - 1983 DA - 1983// TI - Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma JO - Cancer Treat Rep VL - 67 ID - Evans1983 ER - TY - JOUR AU - Harrap, K. R. PY - 1985 DA - 1985// TI - Preclinical studies identifying carboplatin as a viable cisplatin alternative JO - Cancer Treat Rev VL - 12 UR - https://doi.org/10.1016/0305-7372(85)90015-5 DO - 10.1016/0305-7372(85)90015-5 ID - Harrap1985 ER - TY - CHAP AU - Canetta, R. AU - Bragman, K. AU - Smaldone, L. PY - 1988 DA - 1988// BT - Carboplatin: current status and future prospects ID - Canetta1988 ER - TY - JOUR AU - Aabo, K. AU - Adams, M. AU - Adnitt, P. PY - 1998 DA - 1998// TI - Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group JO - Br J Cancer VL - 78 UR - https://doi.org/10.1038/bjc.1998.710 DO - 10.1038/bjc.1998.710 ID - Aabo1998 ER - TY - CHAP AU - Vasey, P. A. AU - Jayson, G. C. AU - Gordon, A. PY - 2004 DA - 2004// BT - Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma ID - Vasey2004 ER - TY - JOUR AU - Dedrick, R. I. AU - Myers, C. E. AU - Bungay, P. M. PY - 1978 DA - 1978// TI - Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer JO - Canc Treat Rep VL - 62 ID - Dedrick1978 ER - TY - JOUR AU - Markman, M. PY - 2001 DA - 2001// TI - Intraperitoneal chemotherapy in the management of malignant disease JO - Exp Rev Anticanc Ther VL - 1 UR - https://doi.org/10.1586/14737140.1.1.142 DO - 10.1586/14737140.1.1.142 ID - Markman2001 ER - TY - JOUR AU - Alberts, D. S. AU - Liu, P. Y. AU - Hannigan, E. V. PY - 1996 DA - 1996// TI - Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer[see comment] JO - N Engl J Med VL - 335 UR - https://doi.org/10.1056/NEJM199612263352603 DO - 10.1056/NEJM199612263352603 ID - Alberts1996 ER - TY - JOUR AU - Markman, M. AU - Bundy, B. N. AU - Alberts, D. S. PY - 2001 DA - 2001// TI - Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group[see comment] JO - J Clin Oncol VL - 19 ID - Markman2001 ER - TY - JOUR AU - Armstrong, D. K. AU - Bundy, B. N. AU - Wenzel, L. PY - 2006 DA - 2006// TI - Intraperitoneal cisplatin and paclitaxel in ovarian cancer JO - N Engl J Med VL - 354 UR - https://doi.org/10.1056/NEJMoa052985 DO - 10.1056/NEJMoa052985 ID - Armstrong2006 ER - TY - JOUR AU - Jaaback, K. AU - Johnson, N. PY - 2006 DA - 2006// TI - Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer JO - Cochrane Database Systemat Rev VL - 25 ID - Jaaback2006 ER - TY - STD TI - NCI Clinical Announcement For Preferred Method of Treatment for Advanced Ovarian Cancer2006. [http://ctep.cancer.gov/resources/gcig/icaoa.html] UR - http://ctep.cancer.gov/resources/gcig/icaoa.html ID - ref46 ER - TY - JOUR AU - Eastman, A. PY - 1987 DA - 1987// TI - The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes JO - Pharmacol Ther VL - 34 UR - https://doi.org/10.1016/0163-7258(87)90009-X DO - 10.1016/0163-7258(87)90009-X ID - Eastman1987 ER - TY - JOUR AU - Gately, D. P. AU - Howell, S. B. PY - 1993 DA - 1993// TI - Cellular accumulation of the anticancer agent cisplatin: a review JO - Br J Cancer VL - 67 UR - https://doi.org/10.1038/bjc.1993.221 DO - 10.1038/bjc.1993.221 ID - Gately1993 ER - TY - JOUR AU - Hahn, G. M. PY - 1979 DA - 1979// TI - Potential for therapy of drugs and hyperthermia JO - Canc Res VL - 39 ID - Hahn1979 ER - TY - JOUR AU - Meyn, R. E. AU - Corry, P. M. AU - Fletcher, S. E. PY - 1980 DA - 1980// TI - Thermal enhancement of DNA damage in mammalian cells treated with cis-diamminedichloroplatinum(II) JO - Cancer Res VL - 40 ID - Meyn1980 ER - TY - JOUR AU - Alberts, D. S. AU - Peng, Y. M. AU - Chen, H. S. PY - 1980 DA - 1980// TI - Therapeutic synergism of hyperthermia-cis-platinum in a mouse tumor model JO - J Nat Cancer Inst VL - 65 ID - Alberts1980 ER - TY - JOUR AU - Los, G. AU - van Vugt, M. J. AU - Pinedo, H. M. PY - 1994 DA - 1994// TI - Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin JO - Brit J Cancer VL - 69 UR - https://doi.org/10.1038/bjc.1994.45 DO - 10.1038/bjc.1994.45 ID - Los1994 ER - TY - JOUR AU - Akaboshi, M. AU - Tanaka, Y. AU - Kawai, K. PY - 1994 DA - 1994// TI - Effect of hyperthermia on the number of platinum atoms binding to DNA of HeLa cells treated with 195mPt-radiolabelled cis-diaminedichloroplatinum(II) JO - Int J Radiat Biol VL - 66 UR - https://doi.org/10.1080/09553009414551121 DO - 10.1080/09553009414551121 ID - Akaboshi1994 ER - TY - JOUR AU - Vaart, P. J. v. a. n. d. e. AU - Vange, N. v. a. n. d. e. r. AU - Zoetmulder, F. A. PY - 1998 DA - 1998// TI - Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines JO - Eur J Cancer VL - 34 UR - https://doi.org/10.1016/S0959-8049(97)00370-5 DO - 10.1016/S0959-8049(97)00370-5 ID - Vaart1998 ER - TY - JOUR AU - Borst, P. AU - Kool, M. AU - Evers, R. PY - 1997 DA - 1997// TI - Do cMOAT (MRP2), other MRP homologues, and LRP play a role in MDR? JO - Semin Cancer Biol VL - 8 UR - https://doi.org/10.1006/scbi.1997.0071 DO - 10.1006/scbi.1997.0071 ID - Borst1997 ER - TY - JOUR AU - Godwin, A. K. AU - Meister, A. AU - O'Dwyer, P. J. PY - 1992 DA - 1992// TI - High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis JO - Proc Natl Acad Sci USA VL - 89 UR - https://doi.org/10.1073/pnas.89.7.3070 DO - 10.1073/pnas.89.7.3070 ID - Godwin1992 ER - TY - CHAP AU - Hamilton, T. AU - Winker, M. AU - Louie, K. PY - 1985 DA - 1985// BT - Augmantation of Adriamycin, melphalan and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian cancer cell lines by buthionine sulfoximine dediated glutathione depletion ID - Hamilton1985 ER - TY - CHAP AU - Dedon, P. AU - Borch, R. E. PY - 1987 DA - 1987// BT - Characterization of the reactions of platinum antitumor agents with biologic and nonbiologic sulfur-containing nucleophiles ID - Dedon1987 ER - TY - JOUR AU - Hosking, L. K. AU - Whelan, R. D. AU - Shellard, S. A. PY - 1990 DA - 1990// TI - An evaluation of the role of glutathione and its associated enzymes in the expression of differential sensitivities to antitumour agents shown by a range of human tumour cell lines JO - Biochem Pharmacol VL - 40 UR - https://doi.org/10.1016/0006-2952(90)90364-Q DO - 10.1016/0006-2952(90)90364-Q ID - Hosking1990 ER - TY - JOUR AU - Kojima, M. AU - Kikkawa, F. AU - Oguchi, H. PY - 1994 DA - 1994// TI - Sensitisation of human ovarian carcinoma cells to cis-diamminedichloroplatinum (II) by amphotericin B in vitro and in vivo JO - Eur J Cancer VL - 30A UR - https://doi.org/10.1016/0959-8049(94)90291-7 DO - 10.1016/0959-8049(94)90291-7 ID - Kojima1994 ER - TY - CHAP AU - Johnson, S. W. AU - Perez, R. P. AU - Godwin, A. K. PY - 1994 DA - 1994// BT - Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines ID - Johnson1994 ER - TY - CHAP AU - Johnson, S. W. AU - Swiggard, P. A. AU - Handel, L. M. PY - 1994 DA - 1994// BT - Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells ID - Johnson1994 ER - TY - JOUR AU - Masuda, H. AU - Tanaka, T. AU - Matsuda, H. PY - 1990 DA - 1990// TI - Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum(II) JO - Cancer Res VL - 50 ID - Masuda1990 ER - TY - CHAP AU - Katz, E. J. AU - Andrews, P. A. AU - Howell, S. B. PY - 1990 DA - 1990// BT - The effect of DNA polymerase inhibitors on the cytotoxicity of cisplatin in human ovarian carcinoma cells ID - Katz1990 ER - TY - JOUR AU - Dempke, W. C. AU - Shellard, S. A. AU - Fichtinger-Schepman, A. M. PY - 1991 DA - 1991// TI - Lack of significant modulation of the formation and removal of platinum-DNA adducts by aphidicolin glycinate in two logarithmically-growing ovarian tumour cell lines in vitro JO - Carcinogenesis VL - 12 UR - https://doi.org/10.1093/carcin/12.3.525 DO - 10.1093/carcin/12.3.525 ID - Dempke1991 ER - TY - CHAP AU - Miller, W. H. AU - Schipper, H. M. AU - Lee, J. S. PY - 2002 DA - 2002// BT - Mechanisms of action of arsenic trioxide ID - Miller2002 ER - TY - CHAP AU - Hartwig, A. AU - Groblinghoff, U. D. AU - Beyersmann, D. PY - 1997 DA - 1997// BT - Interaction of arsenic(III) with nucleotide excision repair in UV-irradiated human fibroblasts ID - Hartwig1997 ER - TY - CHAP AU - Lee, T. C. AU - Tanaka, N. AU - Lamb, P. W. PY - 1988 DA - 1988// BT - Induction of gene amplification by arsenic ID - Lee1988 ER - TY - CHAP AU - Del Razo, L. M. AU - Quintanilla-Vega, B. AU - Brambila-Colombres, E. PY - 2001 DA - 2001// BT - Stress proteins induced by arsenic ID - Del Razo2001 ER - TY - CHAP AU - Leslie, E. M. AU - Haimeur, A. AU - Waalkes, M. P. PY - 2004 DA - 2004// BT - Arsenic transport by the human multidrug resistance protein 1 (MRP1/ABCC1). Evidence that a tri-glutathione conjugate is required ID - Leslie2004 ER - TY - CHAP AU - Shi, H. AU - Hudson, L. G. AU - Ding, W. PY - 2004 DA - 2004// BT - Arsenite causes DNA damage in keratinocytes via generation of hydroxyl radicals ID - Shi2004 ER - TY - CHAP AU - Shi, H. AU - Hudson, L. G. AU - Liu, K. J. PY - 2004 DA - 2004// BT - Oxidative stress and apoptosis in metal ion-induced carcinogenesis ID - Shi2004 ER - TY - CHAP AU - Ramos, A. M. AU - Fernandez, C. AU - Amran, D. PY - 2005 DA - 2005// BT - Pharmacologic inhibitors of PI3K/Akt potentiate the apoptotic action of the antileukemic drug arsenic trioxide via glutathione depletion and increased peroxide accumulation in myeloid leukemia cells ID - Ramos2005 ER - TY - CHAP AU - Hu, J. AU - Fang, J. AU - Dong, Y. PY - 2005 DA - 2005// BT - Arsenic in cancer therapy ID - Hu2005 ER - TY - CHAP AU - Taylor, B. F. AU - McNeely, S. C. AU - Miller, H. L. PY - 2006 DA - 2006// BT - p53 suppression of arsenite-induced mitotic catastrophe is mediated by p21CIP1/WAF1 ID - Taylor2006 ER - TY - CHAP AU - McCollum, G. AU - Keng, P. C. AU - States, J. C. PY - 2005 DA - 2005// BT - Arsenite delays progression through each cell cycle phase and induces apoptosis following G2/M arrest in U937 myeloid leukemia cells ID - McCollum2005 ER - TY - CHAP AU - States, J. C. AU - Reiners, J. J. AU - Pounds, J. G. PY - 2002 DA - 2002// BT - Arsenite disrupts mitosis and induces apoptosis in SV40-transformed human skin fibroblasts. [erratum appears in Toxicol Appl Pharmacol 2002 Sep 1, 183(2):152] ID - States2002 ER - TY - CHAP AU - McCabe, M. J. AU - Singh, K. P. AU - Reddy, S. A. PY - 2000 DA - 2000// BT - Sensitivity of myelomonocytic leukemia cells to arsenite-induced cell cycle disruption, apoptosis, and enhanced differentiation is dependent on the inter-relationship between arsenic concentration, duration of treatment, and cell cycle phase ID - McCabe2000 ER - TY - CHAP AU - Cole, S. P. AU - Sparks, K. E. AU - Fraser, K. PY - 1994 DA - 1994// BT - Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells ID - Cole1994 ER - TY - CHAP AU - Waxman, S. AU - Anderson, K. C. PY - 2001 DA - 2001// BT - History of the development of arsenic derivatives in cancer therapy ID - Waxman2001 ER - TY - JOUR AU - Liu, J. AU - Lu, Y. AU - Wu, Q. PY - 2008 DA - 2008// TI - Mineral arsenicals in traditional medicines: orpiment, realgar, and arsenolite JO - J Pharmacol Exp Ther VL - 326 UR - https://doi.org/10.1124/jpet.108.139543 DO - 10.1124/jpet.108.139543 ID - Liu2008 ER - TY - CHAP AU - Cohen, M. H. AU - Hirschfeld, S. AU - Flamm Honig, S. PY - 2001 DA - 2001// BT - Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene ID - Cohen2001 ER - TY - CHAP AU - Murgo, A. J. AU - McBee, W. L. AU - Cheson, B. D. PY - 2000 DA - 2000// BT - Clinical trials referral resource. Clinical trials with arsenic trioxide ID - Murgo2000 ER - TY - CHAP AU - Murgo, A. J. PY - 2001 DA - 2001// BT - Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies ID - Murgo2001 ER - TY - JOUR AU - Du, Y. H. AU - Ho, P. C. AU - Du, Y. H. PY - 2001 DA - 2001// TI - Arsenic compounds induce cytotoxicity and apoptosis in cisplatin-sensitive and -resistant gynecological cancer cell lines JO - Cancer Chemother Pharmacol VL - 47 UR - https://doi.org/10.1007/s002800100278 DO - 10.1007/s002800100278 ID - Du2001 ER - TY - CHAP AU - Uslu, R. AU - Sanli, U. A. AU - Sezgin, C. PY - 2000 DA - 2000// BT - Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines ID - Uslu2000 ER - TY - JOUR AU - Bornstein, J. AU - Sagi, S. AU - Haj, A. PY - 2005 DA - 2005// TI - Arsenic Trioxide inhibits the growth of human ovarian carcinoma cell line JO - Gynecol Oncol VL - 99 UR - https://doi.org/10.1016/j.ygyno.2005.07.125 DO - 10.1016/j.ygyno.2005.07.125 ID - Bornstein2005 ER - TY - JOUR AU - Kong, B. AU - Huang, S. AU - Wang, W. PY - 2005 DA - 2005// TI - Arsenic trioxide induces apoptosis in cisplatin-sensitive and -resistant ovarian cancer cell lines JO - Int J Gynecol Cancer VL - 15 UR - https://doi.org/10.1111/j.1525-1438.2005.00251.x DO - 10.1111/j.1525-1438.2005.00251.x ID - Kong2005 ER - TY - JOUR AU - Zhang, J. AU - Wang, B. PY - 2006 DA - 2006// TI - Arsenic trioxide (As(2)O(3)) inhibits peritoneal invasion of ovarian carcinoma cells in vitro and in vivo JO - Gynecol Oncol VL - 103 UR - https://doi.org/10.1016/j.ygyno.2006.02.037 DO - 10.1016/j.ygyno.2006.02.037 ID - Zhang2006 ER - TY - JOUR AU - Baumgartner, M. AU - Sturlan, S. AU - Roth, E. PY - 2004 DA - 2004// TI - Enhancement of arsenic trioxide-mediated apoptosis using docosahexaenoic acid in arsenic trioxide-resistant solid tumor cells JO - Int J Cancer VL - 112 UR - https://doi.org/10.1002/ijc.20462 DO - 10.1002/ijc.20462 ID - Baumgartner2004 ER - TY - CHAP AU - Wang, W. AU - Qin, S. K. AU - Chen, B. A. PY - 2001 DA - 2001// BT - Experimental study on antitumor effect of arsenic trioxide in combination with cisplatin or doxorubicin on hepatocellular carcinoma ID - Wang2001 ER -